Literature DB >> 26039296

Combined therapy of Ulmo honey (Eucryphia cordifolia) and ascorbic acid to treat venous ulcers.

Mariano del Sol Calderon1, Carolina Schencke Figueroa2, Jessica Salvo Arias3, Alejandra Hidalgo Sandoval4, Felipe Ocharan Torre4.   

Abstract

OBJECTIVE: to assess the clinical effect of topical treatment using Ulmo honey associated with oral ascorbic acid in patients with venous ulcers.
METHOD: longitudinal and descriptive quantitative study. During one year, 18 patients were assessed who were clinically diagnosed with venous ulcer in different stages, male and female, adult, with a mean injury time of 13 months. Ulmo honey was topically applied daily. The dressing was applied in accordance with the technical standard for advanced dressings, combined with the daily oral consumptions of 500 mg of ascorbic acid. The monitoring instrument is the assessment table of venous ulcers.
RESULTS: full healing was achieved in 100% of the venous ulcers. No signs of complications were observed, such as allergies or infection.
CONCLUSION: the proposed treatment showed excellent clinical results for the healing of venous ulcers. The honey demonstrated debriding and non-adherent properties, was easy to apply and remove and was well accepted by the users. The described results generated a research line on chronic wound treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26039296      PMCID: PMC4458999          DOI: 10.1590/0104-1169.0020.2550

Source DB:  PubMed          Journal:  Rev Lat Am Enfermagem        ISSN: 0104-1169


  16 in total

Review 1.  The role of honey in the management of wounds.

Authors:  P C Molan
Journal:  J Wound Care       Date:  1999-09       Impact factor: 2.072

2.  The sensitivity to honey of Gram-positive cocci of clinical significance isolated from wounds.

Authors:  R A Cooper; P C Molan; K G Harding
Journal:  J Appl Microbiol       Date:  2002       Impact factor: 3.772

3.  Effect of ascorbic Acid on incisional wound healing in streptozotocin-induced diabetic rats.

Authors:  Erdinc Kamer; Haluk Recai Unalp; Omer Gundogan; Gulden Diniz; Ragip Ortac; Murat Olukman; Hayrullah Derici; Mehmet Ali Onal
Journal:  Wounds       Date:  2010-02       Impact factor: 1.546

4.  Use of platelet-rich plasma in the healing of chronic ulcers of the lower extremity.

Authors:  A E Salazar-Álvarez; L F Riera-del-Moral; M García-Arranz; J Alvarez-García; N A Concepción-Rodriguez; L Riera-de-Cubas
Journal:  Actas Dermosifiliogr       Date:  2014-03-12

5.  Antioxidant status in delayed healing type of wounds.

Authors:  A M Rasik; A Shukla
Journal:  Int J Exp Pathol       Date:  2000-08       Impact factor: 1.925

6.  Comparison of the antimicrobial activity of Ulmo honey from Chile and Manuka honey against methicillin-resistant Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

Authors:  Orla Sherlock; Anthony Dolan; Rahma Athman; Alice Power; Georgina Gethin; Seamus Cowman; Hilary Humphreys
Journal:  BMC Complement Altern Med       Date:  2010-09-02       Impact factor: 3.659

Review 7.  Systematic review of topic treatment for venous ulcers.

Authors:  Eline Lima Borges; Maria Helena Larcher Caliri; Vanderlei José Haas
Journal:  Rev Lat Am Enfermagem       Date:  2007 Nov-Dec

8.  Honey stimulates inflammatory cytokine production from monocytes.

Authors:  A J Tonks; R A Cooper; K P Jones; S Blair; J Parton; A Tonks
Journal:  Cytokine       Date:  2003-03-07       Impact factor: 3.861

9.  Manuka honey vs. hydrogel--a prospective, open label, multicentre, randomised controlled trial to compare desloughing efficacy and healing outcomes in venous ulcers.

Authors:  Georgina Gethin; Seamus Cowman
Journal:  J Clin Nurs       Date:  2008-08-23       Impact factor: 3.036

10.  [People with vascular ulcers in outpatient nursing care: a study of sociodemographic and clinical variables].

Authors:  Suelen Gomes Malaquias; Maria Márcia Bachion; Silvia Maria Soares Carvalho Sant'ana; Ceres Cristina Bueno Dallarmi; Ruy de Souza Lino Junior; Priscilla Santos Ferreira
Journal:  Rev Esc Enferm USP       Date:  2012-04       Impact factor: 1.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.